NCT02862600 - Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2016

Primary Completion Date

April 28, 2017

Study Completion Date

May 22, 2017

Conditions

Cardiomyopathy, HypertrophicCardiomyopathy, Hypertrophic, Familial

Interventions

DRUG

Perhexiline

Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline

DEVICE

Use of bioanalytical assay to monitor plasma levels of perhexiline

The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.

Trial Locations (11)

Unknown

Stanford

Indianapolis

Johns Hopkins, Baltimore

University of Maryland, Baltimore

Detroit

Columbus

Portland

Hershey

Germantown

Salt Lake City

Madison